Fuji Pharma Co., Ltd.
TSE:4554.T
1289 (JPY) • At close November 5, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) JPY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 40,889 | 35,426 | 33,990 | 33,793 | 36,279 | 37,909 | 35,387 | 34,229 | 31,680 | 29,215 | 25,174 | 21,522.065 | 21,623.812 | 19,701.956 | 17,201.236 | 14,940.538 |
| Kosten van de omzet
| 24,374 | 20,867 | 19,239 | 18,921 | 20,483 | 21,959 | 20,671 | 20,691 | 18,709 | 16,835 | 14,233 | 12,203.976 | 11,323.822 | 10,622.566 | 9,405.783 | 8,471.393 |
| Brutowinst
| 16,515 | 14,559 | 14,751 | 14,872 | 15,796 | 15,950 | 14,716 | 13,538 | 12,971 | 12,380 | 10,941 | 9,318.089 | 10,299.99 | 9,079.39 | 7,795.453 | 6,469.145 |
| Brutowinstmarge
| 0.404 | 0.411 | 0.434 | 0.44 | 0.435 | 0.421 | 0.416 | 0.396 | 0.409 | 0.424 | 0.435 | 0.433 | 0.476 | 0.461 | 0.453 | 0.433 |
| Onderzoek- en ontwikkelingskosten
| 3,184 | 2,485 | 2,446 | 3,060 | 2,052 | 1,760 | 1,825 | 1,840 | 1,729 | 1,769 | 1,280 | 1,303.775 | 1,516.407 | 1,114.446 | 918.821 | 625.544 |
| Algemene en administratieve kosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,037.206 | 1,228.656 | 1,137.953 | 1,020.026 | 931.096 |
| Verkoop- en marketingkosten
| 0 | 0 | 1,345 | 1,489 | 1,888 | 1,819 | 1,537 | 1,257 | 1,406 | 1,125 | 1,038 | 1,030.805 | 968.239 | 723.44 | 621.649 | 431.005 |
| Verkoop-, algemene en administratieve kosten
| 8,331 | 7,355 | 1,345 | 1,489 | 1,888 | 1,819 | 1,537 | 1,257 | 1,406 | 1,125 | 1,038 | 2,068.011 | 2,196.895 | 1,861.393 | 1,641.675 | 1,362.101 |
| Overige kosten
| 213 | 8,292 | 7,607 | 7,179 | 7,678 | 93 | 9 | 27 | 18 | 65 | 52 | 24.261 | -2.986 | 8.378 | 11.176 | 14.126 |
| Bedrijfskosten
| 12,652 | 10,777 | 11,398 | 11,728 | 11,618 | 11,555 | 10,397 | 9,964 | 9,715 | 9,203 | 7,675 | 5,823.098 | 5,960.495 | 5,142.124 | 4,674.4 | 3,779.936 |
| Bedrijfsresultaat
| 3,858 | 3,777 | 3,349 | 3,139 | 4,173 | 4,391 | 4,314 | 3,568 | 3,251 | 3,173 | 3,261 | 3,494.991 | 4,339.495 | 3,937.266 | 3,121.053 | 2,689.209 |
| Bedrijfsresultaat ratio
| 0.094 | 0.107 | 0.099 | 0.093 | 0.115 | 0.116 | 0.122 | 0.104 | 0.103 | 0.109 | 0.13 | 0.162 | 0.201 | 0.2 | 0.181 | 0.18 |
| Totaal overige inkomsten en kosten netto
| 541 | -54 | 22 | -221 | -212 | 77 | 212 | -425 | -150 | 56 | 66 | -1,169.148 | -842.635 | -781.047 | -651.675 | -659.181 |
| Inkomen voor belasting
| 4,399 | 3,723 | 3,371 | 2,918 | 3,961 | 4,472 | 4,530 | 3,148 | 3,105 | 3,232 | 3,332 | 2,325.843 | 3,496.86 | 3,156.219 | 2,469.378 | 2,030.028 |
| Inkomen voor belasting ratio
| 0.108 | 0.105 | 0.099 | 0.086 | 0.109 | 0.118 | 0.128 | 0.092 | 0.098 | 0.111 | 0.132 | 0.108 | 0.162 | 0.16 | 0.144 | 0.136 |
| Belastingkosten
| 963 | 1,026 | 938 | 832 | 998 | 1,099 | 1,228 | 1,029 | 1,012 | 1,153 | 1,264 | 954.912 | 1,292.014 | 1,212.147 | 943.42 | 778.314 |
| Nettowinst
| 3,435 | 2,696 | 2,432 | 2,085 | 2,962 | 3,372 | 3,301 | 2,118 | 2,092 | 2,078 | 2,068 | 1,370.93 | 2,204.846 | 1,944.071 | 1,525.958 | 1,251.714 |
| Nettowinstmarge
| 0.084 | 0.076 | 0.072 | 0.062 | 0.082 | 0.089 | 0.093 | 0.062 | 0.066 | 0.071 | 0.082 | 0.064 | 0.102 | 0.099 | 0.089 | 0.084 |
| WPA (Winst Per Aandeel)
| 141.35 | 110.98 | 90.52 | 66.92 | 97.02 | 112.67 | 110.32 | 70.82 | 68.78 | 70.27 | 73.24 | 48.55 | 83.82 | 75.53 | 59.29 | 48.63 |
| Verwaterde WPA
| 141.35 | 110.98 | 90.52 | 66.92 | 97.02 | 112.67 | 110.32 | 70.82 | 68.78 | 70.27 | 73.24 | 48.55 | 83.82 | 75.53 | 59.29 | 48.63 |
| EBITDA
| 7,285 | 6,833 | 5,408 | 5,077 | 6,222 | 6,761 | 6,684 | 5,206 | 5,215 | 4,901 | 4,843 | 4,663.368 | 5,345.004 | 4,974.962 | 4,089.409 | 3,515.96 |
| EBITDA ratio
| 0.178 | 0.193 | 0.159 | 0.15 | 0.172 | 0.178 | 0.189 | 0.152 | 0.165 | 0.168 | 0.192 | 0.217 | 0.247 | 0.253 | 0.238 | 0.235 |